Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19-Reference-Cited by-同舟云学术

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19

Published:2024-01-18 Issue:3 Volume:390 Page:230-241
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Cao Bin¹,Wang Yeming¹,Lu Hongzhou¹,Huang Chaolin¹,Yang Yumei¹,Shang Lianhan¹,Chen Zhu¹,Jiang Rongmeng¹,Liu Yihe¹,Lin Ling¹,Peng Ping¹,Wang Fuxiang¹,Gong Fengyun¹,Hu Honglin¹,Cheng Cong¹,Yao Xiangyang¹,Ye Xianwei¹,Zhou Hourong¹,Shen Yinzhong¹^ORCID,Liu Chenfan¹,Wang Chunying¹,Yi Zhennan¹,Hu Bijie¹,Xu Jiuyang¹^ORCID,Gu Xiaoying¹,Shen Jingshan¹,Xu Yechun¹,Zhang Leike¹,Fan Jia¹,Tang Renhong¹,Wang Chen¹

Affiliation:

1. From the Departments of Pulmonary and Critical Care Medicine (B.C., Y.W., L.S., J.X., Chen Wang) and Clinical Research and Data Management (X.G.), Institute of Respiratory Medicine in the Chinese Academy of Medical Sciences, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China–Japan Friendship Hospital, Changping Laboratory (B.C., Chen Wang), the Department of Medicine, Non-oncology, Jiangsu Simcere Pharmaceutical (Y.Y.), Clinical and Research...

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2301425

Reference22 articles.

1. Johns Hopkins Coronavirus Resource Center. COVID-19 dashboard (https://coronavirus.jhu.edu/map.html).

2. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

3. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution.;Cao Y;Nature,2023

4. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. News release of the Food and Drug Administration Silver Spring MD December 22 2021 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19).

5. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deep representation learning from electronic medical records identifies distinct symptom based subtypes and progression patterns for COVID-19 prognosis;International Journal of Medical Informatics;2024-11

2. N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease;European Journal of Medicinal Chemistry;2024-10

3. A Gaussia luciferase reporter assay for the evaluation of coronavirus Nsp5/3CLpro activity;Scientific Reports;2024-09-05

4. Structural review of SARS-CoV-2 antiviral targets;Structure;2024-09

5. SARS-CoV-2 antivirals and post-COVID-19 condition;The Lancet Infectious Diseases;2024-09